Semaglutide effects, told the way people actually describe them.

The short version

Two stories run side by side with semaglutide, and this page keeps them apart on purpose. The first is what people say it does: for many, the constant mental chatter about food goes quiet, cravings fade, and weight comes off steadily over months. People with diabetes often describe better blood-sugar numbers. The second is the cost, and it is mostly in the gut: nausea, foul-smelling burps, changed bowel habits, tiredness early on. Those reports are real experiences but they are anecdote — not measured trial data. Below, the first part is exactly that: things people report, clearly labeled. The second part, the safety and cautions, is drawn from the published clinical record and is cited to specific studies. Nothing here is a dose, an instruction, or medical advice. It is a plain-English reading of semaglutide effects from two different kinds of evidence, kept clearly separate.

What people report

These are effects described by people using semaglutide in research-use and patient communities. They are anecdotal, not clinical evidence, and they have not been confirmed by controlled trials. No doses are attached, and a reported effect is not a proven one.

Benefits people describe most often

• A quieter relationship with food (frequently reported). By far the most common thing people describe is that the background "food noise" goes quiet, often within the first week or two. They feel full faster, eat a third to a half of old portions, and stop circling the next meal. Many call this the single most life-changing effect.
• Cravings drop (frequently reported). Sweet-tooth and sugar cravings fall sharply or vanish; fried, greasy, high-fat foods stop appealing and can turn slightly off-putting. Several say they drift naturally toward fruit, vegetables, and lighter meals.
• Weight loss (frequently reported). The large majority report losing weight, often steady and substantial over several months, with the pace slowing after the early stretch. Many tie it directly to eating much less rather than to exercise.
• Steadier blood sugar (commonly reported). Among people with type 2 diabetes, a common theme is markedly better blood-sugar and A1C readings, with some describing fasting numbers settling into normal ranges and steadier daytime energy.
• Less desire to drink alcohol (occasionally reported). A recurring side observation is that the urge to drink fades along with food cravings; some simply lose interest. Patient communities discuss this widely as an unexpected bonus.

Downsides people describe most often

• Nausea, sometimes with vomiting (frequently reported). Nausea is the single most reported side effect, named by roughly a third of reviewers, and a subset escalates to vomiting at its worst. It tends to peak in the first weeks and after each step up in dose, often easing within a week or two, and flares after overeating or fatty food.
• Sulfur or "egg" burps (commonly reported). A distinctive complaint: foul-smelling burps likened to rotten eggs or sulfur, often arriving after a dose increase, sometimes lasting hours or weeks before settling, frequently with bloating and a sense of food sitting too long.
• Changed bowel habits (commonly reported). Both constipation and diarrhea show up, sometimes alternating — hard, infrequent stools for some; looser stools worse right after a dose or after rich food for others.
• Acid reflux and heartburn (occasionally reported). Reflux and indigestion, sometimes severe, often alongside burping and bloating, tracking with dose increases.
• Fatigue early on (commonly reported). Tiredness and low energy, especially the day or two after an injection and during the early weeks, usually easing with time.
• Food aversions and taste changes (occasionally reported). Active aversions to fatty, fried, or meaty food, a metallic taste, and a heightened, sometimes unpleasant sensitivity to smells that can itself trigger nausea — often likened to morning sickness. A few find appetite suppressed so far they must remind themselves to eat.
• Hair shedding and a gaunter face (sometimes reported). A smaller group notices more hair shedding a few months in, and a thinner, more hollow face — both widely attributed to losing weight quickly rather than to the drug, with the shedding usually described as temporary.
• Headaches and dizziness (occasionally reported). Often in the first days of a new dose and frequently linked to drinking too little or eating too little; many say hydration helps.
• Injection-site reactions (sometimes reported). Mild redness, itching, a small bump, or tenderness where injected — generally minor and short-lived.

Safety & cautions

These cautions are drawn from the published clinical and pharmacovigilance record and are cited. Some are confirmed trial findings; some are precautionary or theoretical, and where that is the case it is said plainly. None of this is dosing advice.

Gut intolerance, especially while the dose is climbing. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in the trials and the leading reason people stop. In a pooled analysis of the weight-management program these events were mostly mild-to-moderate and transient, clustered around the dose-escalation period ^[23], and a dedicated safety review reported nausea in roughly a third of patients ^[5]; real-world reporting is likewise dominated by gut events ^[24]. This is mechanism, not mystery: the slowed stomach-emptying that drives the gut effects is part of how the drug works.

A personal or family history of medullary thyroid cancer, or MEN-2 (boxed warning). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, derived from rodents given very high exposures. A dedicated review of thyroid risk concluded that human data do not establish a clear increase in thyroid cancer attributable to semaglutide — so the cancer signal is best read as unconfirmed in humans — yet a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a reason not to use it, on the strength of the animal finding ^[25][5].

Acute pancreatitis (class warning). Inflammation of the pancreas is a recognized class warning, and treatment is conventionally stopped if it is suspected. A dedicated safety review notes that pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn because the numbers are low, rather than confirmed associations — so this caution is precautionary, not a demonstrated risk increase ^[5].

Gallbladder and bile-duct disease. A safety review found an increased risk of gallstone-related disease with semaglutide, attributed largely to the speed and size of weight loss rather than a direct toxic effect — but the increase versus placebo is a real trial and reporting finding, not merely theoretical ^[5].

Pre-existing diabetic eye disease with fast blood-sugar correction. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent on semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated in people who already had retinopathy and whose blood sugar was lowered quickly ^[2]. The leading interpretation is early worsening from the speed of correction rather than direct harm to the retina; monitoring is advised when glucose is corrected rapidly ^[5].

Loss of muscle along with fat. A body-composition substudy using DXA scans reported that the weight lost included both fat and a meaningful share of lean (muscle) mass ^[20]. Because rapid, large weight loss can erode muscle, this raises a concern about sarcopenia (age- or illness-related muscle loss), especially in older adults — an extrapolated, mechanism-based worry, not a proven outcome — and has driven research into protein intake and resistance training.

Weight regain after stopping. Stopping is followed by substantial regain. In the STEP 1 extension, people regained a mean of roughly 11.6 percentage points of body weight within a year of stopping, and cardiometabolic gains drifted back toward baseline ^[21]; the STEP 4 withdrawal design likewise showed regain after a switch to placebo ^[22]. This frames weight pharmacotherapy as ongoing rather than curative.

Hair shedding with rapid weight loss. A pharmacovigilance analysis flagged a reporting signal for hair loss with semaglutide and a related drug ^[14], and a separate dermatology study linked telogen effluvium — a reversible, diffuse shedding — to the size and speed of weight loss ^[15]. The signal fits weight-loss-driven shedding rather than a direct toxic effect.

Pregnancy. Semaglutide is contraindicated in pregnancy per the approved labeling. Because the half-life is about a week, with effectively complete clearance only around five weeks after the last dose, label guidance advises stopping well before a planned pregnancy (commonly cited as roughly two months) ^[17].

The oral form needs a strict empty stomach. Oral semaglutide is paired with an absorption enhancer called SNAC and has very low oral availability (about 0.4-1%), so it must be taken fasted with only a little water, apart from other food, drink and medicine; getting that wrong can sharply cut how much is absorbed ^[18]. This is a formulation requirement, not a toxicity.

<a id="semaglutide-side-effects"></a> Semaglutide side effects, in brief. Pulling the threads together: the most common semaglutide side effects are gastrointestinal and front-loaded into the titration period — nausea, vomiting, diarrhea, constipation, reflux and the distinctive sulfur burps — mostly mild-to-moderate and transient ^[23][5]. The serious-but-rarer cautions (thyroid C-cell boxed warning, pancreatitis class warning, gallbladder disease, retinopathy with rapid correction) sit above, each tied to its source.

Compounded semaglutide

During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to prepare semaglutide outside the approved manufactured product. That window is the source of the term compounded semaglutide. Regulators documented dosing errors, adverse events requiring hospitalization, and products with unverified or non-pharmaceutical active ingredients during that period, and the compounding pathways were curtailed once the shortage was declared resolved in 2025 ^[5]. The plain point: compounded or non-pharmaceutical sources fall outside the approved-product evidence base that every trial on this site studied, and carry documented quality and safety concerns. This page describes the published record; it is not a recommendation to obtain the drug from any particular source.

Then and now

Semaglutide is the product of decades of incretin-peptide chemistry, engineered for once-weekly dosing on the foundation of an earlier GLP-1 analogue. It first reached approval for type 2 diabetes in 2017, gained an oral once-daily form in 2019-2020, and a chronic weight-management use in 2021 ^[1]. Its cardiovascular-outcomes evidence read out in SELECT in 2023 ^[3] and its kidney-outcomes evidence in FLOW in 2024 ^[6], with the corresponding heart and kidney indications following, and a fatty-liver (MASH) indication arriving in 2025 ^[16]. It has been an approved medicine throughout — this notebook reads that approved record, not a research chemical.